India set to roll out bedaquiline to combat extensively drug-resistant TB

15 February 2016

A new drug to treat extensively drug resistant tuberculosis (XDR-TB), bedaquiline, is set to open a new chapter in India and is to be introduced in government facilities at selected centers across the country, reports The Pharma Letter’s India correspondent.

Expected to bring hope to thousands affected by the drug resistant disease, the 'miracle drug' is soon to become available as part of a second line treatment of tuberculosis for patients suffering from multi-drug resistance (MDR) and extensively drug resistant (XDR) strains of the bacteria, according to the Indian Council of Medical Research.

Dr Jagdish Prasad, Director General of Health Services, said the drug would be made available soon across India. It recently underwent clinical trials at the national level in certain hospitals for safety and efficacy results.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK